EU/3/14/1244: Orphan designation for the treatment of polycythaemia vera
Ruxolitinib
Table of contents
Overview
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in February 2015 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.
On 19 February 2014, orphan designation (EU/3/14/1244) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for ruxolitinib for treatment of polycythaemia vera.
Key facts
Active substance |
Ruxolitinib
|
Intended use |
Treatment of polycythaemia vera
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/14/1244
|
Date of designation |
19/02/2014
|
Sponsor |
Novartis Europharm Limited |
Review of designation
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in February 2015 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: